Combining plasma NT-proBNP testing with the E/E(m) ratio significantly predicted all-cause mortality or HF-related hospital admissions in patients with stable systolic heart failure.
Cohort (n=362)
Does the combination of E/E(m) ratio and NT-proBNP testing improve risk stratification for all-cause mortality or HF-related hospital admissions in outpatients with chronic systolic HF?
Combining NT-proBNP testing with E/E(m) ratio improves risk stratification in stable systolic heart failure patients, particularly those with mild diastolic dysfunction.
p-value: p=< 0.0001
AIMS: This study was designed to ascertain whether the combination of Doppler assessment of the ratio of mitral blood flow to myocardial early diastolic velocities (E/E(m) ratio) and plasma N-terminal pro-type B natriuretic peptide (NT-proBNP) testing is useful to better stratify patients with stable systolic heart failure (HF). METHODS AND RESULTS: A total of 362 outpatients with chronic systolic HF (left ventricular ejection fraction or=12), 77% in those with the E/E(m) ratio in the intermediate third, and 86% in those with the E/E(m) ratio in the lower third (<or=7) (P< 0.0001). By stratifying patients according to NT-proBNP above the median, patients' outcome was predicted in 13 out of 17 in the intermediate third (P = 0.002) and in 9 out of 10 in the lower third of E/E(m) ratio (P= 0.005). CONCLUSION: In patients with stable HF categorized according to the E/E(m) ratio, NT-proBNP testing improves risk stratification, particularly in those with minor degrees of diastolic dysfunction.
Dini et al. (Mon,) conducted a cohort in chronic systolic heart failure (n=362). E/E(m) ratio and NT-proBNP testing was evaluated on All-cause mortality or HF-related hospital admissions (p=< 0.0001). Combining plasma NT-proBNP testing with the E/E(m) ratio significantly predicted all-cause mortality or HF-related hospital admissions in patients with stable systolic heart failure.